CAN 296

Drug Profile

CAN 296

Alternative Names: CAN-296

Latest Information Update: 19 Mar 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlycoGenesys
  • Class Antifungals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 27 Aug 2003 This compound is still in active development
  • 17 May 2001 This compound is still in active development
  • 21 May 1999 SafeScience has been awarded a US patent covering the use of CAN 296 and analogues in the treatment of fungal disease in animals and humans
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top